OBJECTIVES The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention.
By lacking a contemporary control group, however, most of these registries failed in providing important information on the comparative efficacy and safety of ABSORB BRS and current-generation DES. In contrast, the few ABSORB BRS studies where a control group was available were typically limited by the small sample size and/or patients' selection (10) (11) (12) (13) (14) (15) (16) (17) .
In the GHOST-EU (Gauging coronary Healing with bioresorbable Scaffolding plaTforms in EUrope) registry, the largest series of ABSORB BRS published so far, follow-up information was available in 76% of patients at 6 months and no comparison versus contemporary DES was available (5) . These issues complicate the interpretation of the study, which showed acceptable rates of target lesion failure at 6 months but unexpectedly high rates of scaffold thrombosis mainly clustered within 30 days after implantation. To meaningfully reappraise the safety and efficacy of the ABSORB BRS in the GHOST-EU registry, with extended follow-up information now available, and to put these results into perspective of contemporary PCI outcomes with second-generation DES in the real world, we 
CHARACTERISTICS OF PATIENTS MATCHED FOR PROPENSITY
SCORE. After propensity score matching was performed
Bioresorbable Scaffolds In Routine Clinical Practice
for the entire population (N ¼ 6,223), there were 905 matched pairs of patients ( Table 2 ). In this matched cohort, the mean age was 63 years, men accounted for 78% of patients, and diabetes mellitus was recorded in 27%. A total of 42% of patients presented with an acute coronary syndrome, 59% had multivessel disease, and 55% had 1 or more ACC/AHA B2/C lesion(s). The mean lesion reference vessel diameter and length were 3 and 18 mm, respectively. In the matched cohorts, there was no longer any significant difference between the ABSORB BRS and the XIENCE EES group for any covariate ( Table 2) . Values are mean AE SD (N) or % (n/N). p Values are from tests for matched data.
1-YEAR OUTCOMES OF THE MATCHED COHORTS.
Abbreviations as in Table 1 . Tamburino et al.
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Bioresorbable Scaffolds In Routine Clinical Practice Conversely, in GHOST-EU, scaffolds were less likely to be placed in lesions where high radial strength is necessary (i.e., ostial, in-stent restenosis), in keeping with observational data from bench testing (22) .
PREVIOUS STUDIES OF ABSORB BRS VERSUS DES.
Six randomized studies have reported comparative data of ABSORB BRS versus DES so far. In the ABSORB II trial, ABSORB BRS were compared 2:1 to XIENCE EES in 501 patients with mostly ACC/AHA class B lesions 
respectively (p ¼ 0.62) (16) . Finally, the pivotal U.S.
trial ABSORB III randomized 2:1 a total of 1,322 patients to ABSORB BRS and 686 patients to XIENCE EES (17) . 
COMPARATIVE OUTCOMES OF ABSORB BRS AND
XIENCE EES IN THE MATCHED COHORTS. At 1 year, the rate of DOCE in our matched cohort of ABSORB BRS (n ¼ 905) was found to be 5.8%. In a previous report of the unmatched GHOST-EU population, the rate of DOCE at 6 months was 4.4%. In the present study, the observed rate of DOCE was not statistically different Thanks to the availability of the large XIENCE V USA cohort for this analysis, we were able to match threefourths of the 1,189 patients included in the original GHOST-EU publication (Online Table 2 for a comparison of matched versus unmatched patients in GHOST-EU).
On the other hand, this study carries a number of limitations. The most important limitation is the lack of a random assignment to the treatment groups.
Evaluating the effect of a specific treatment using a registry can lead to incorrect conclusions because of the influence of unidentified confounding variables.
To partly compensate for the baseline and angio- Tamburino et al.
